Overview

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2031-12-31

Target enrollment:

Participant gender:

Summary

Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment

Phase:

PHASE2

Details

Lead Sponsor:

Yeon Hee Park

Treatments:

Fulvestrant
ribociclib